Keyphrases
Migraine
98%
Headache
55%
Calcitonin Gene-related Peptide
32%
Migraine Attack
30%
Migraine without Aura (MWoA)
25%
Chronic Migraine
23%
Single Center
19%
Denmark
19%
Erenumab
18%
Placebo
17%
Migraine Treatment
16%
Calcitonin Receptor
15%
New Drugs
12%
Headache Disorders
11%
Monoclonal Antibody
11%
Migraine Prevention
10%
Red Flags
10%
Trigeminovascular System
10%
Monthly Migraine Days
10%
Adverse Events
10%
Fremanezumab
9%
Nationwide Cross-sectional Survey
9%
Tolerability
9%
Placebo-controlled
9%
Neurology Resident
9%
Prospective Observational Study
9%
Tension-type Headache
9%
NewHope
9%
YouTube
9%
Botulinum Neurotoxin (BoNT)
9%
Clinical Management
9%
Visual Aura
9%
Migraine Management
8%
Calcitonin Gene-related Peptide Monoclonal Antibody
8%
Preventive Treatment
7%
Healthcare Professionals
7%
Peptide Signaling
7%
Randomized Double-blind
7%
Healthy Volunteers
7%
Prophylactic Treatment
7%
Secondary Headache
7%
Gepants
7%
Receptor Activation
6%
Non-pharmacological Therapy
6%
World Wide Web
6%
Treatment-resistant
6%
Migraine Drugs
6%
Google
6%
Visual Symptoms
6%
Antibody Targeting
5%
Medicine and Dentistry
Migraine
81%
Headache
53%
Calcitonin Gene Related Peptide
23%
Cross Sectional Study
18%
Monoclonal Antibody
16%
Erenumab
11%
Headache and Facial Pain
10%
Calcitonin Gene Related Peptide Receptor
10%
Drug Therapy
10%
Transformed Migraine
10%
Migraine Aura
10%
Placebo
9%
Neurology
9%
Botulinum Toxin A
9%
Observational Study
9%
Systematic Review
9%
Tension Headache
9%
Botulinum Toxin
9%
Hope
9%
Volunteer
7%
Symptom
7%
Cervicogenic Headache
7%
Diagnosis
6%
Migraine Treatment
5%
Disease
5%
Prophylaxis
5%
Fremanezumab
5%
Cohort Effect
5%
Clinical Feature
5%
Receptor Blocking
5%
Migraine without Aura
5%
Pharmacology, Toxicology and Pharmaceutical Science
Migraine
100%
Calcitonin Gene Related Peptide
38%
Headache
26%
Monoclonal Antibody
23%
Transformed Migraine
23%
Erenumab
19%
Observational Study
18%
Pharmacotherapy
18%
Adverse Event
15%
Calcitonin Gene Related Peptide Receptor
15%
Placebo
15%
Fremanezumab
12%
Botulinum Toxin
9%
Botulinum Toxin A
9%
Symptom
7%
Tolerability
7%
Migraine without Aura
5%
Receptor
5%